Business Wire

Clasp Therapeutics Launches With $150 Million to Pioneer Precision Immuno-Oncology Using Next-Generation T Cell Engagers With Unparalleled Specificity

CAMBRIDGE, Mass. & ROCKVILLE, Md.--(BUSINESS WIRE)--Clasp Therapeutics, a biotechnology company bringing unparalleled precision to immuno-oncology using next-generation T cell engagers (TCEs), ...
Business Wire

Clasp Therapeutics Doses First Patient in Phase 1 Clinical Trial With a First-in-Class T-Cell Engager Designed to Target Cancer Cells With Absolute Specificity

- CLSP-1025 targets the most common p53 mutation, a key oncogenic driver associated with multiple types of solid tumors, including gastrointestinal, lung, and gynecological cancers - Clasp's pHLAre™ ...
Yahoo Finance

Clasp Therapeutics Presents Comprehensive Preclinical Data Validating First-in-Class Precision T Cell Engager Against p53 Mutant Solid Tumors at SITC Annual Meeting

CAMBRIDGE, MA. & ROCKVILLE, MD., November 07, 2024--(BUSINESS WIRE)--Clasp Therapeutics, a biotechnology company bringing unparalleled precision to immuno-oncology using next-generation TCEs, today ...
YouTube on MSN

How to make simple braid 3 wire bracelet | beautiful with flower clasp | tutorial beads jewelry 1014

tutorial for making simple jewelry from copper wire, stone and bead from LanAnhHandmade. The method is simple, easy to understand and completely free. In this video, we will learn how to make a simple ...
Yahoo Finance

Clasp Therapeutics Doses First Patient in Phase 1 Clinical Trial With a First-in-Class T-Cell Engager Designed to Target Cancer Cells With Absolute Specificity

- Clasp's pHLAre™ platform is optimized for tumor-specific antigens, with the potential to yield safer and more effective precision immunotherapies - Preclinical data presented at the 2025 American ...